GlaxoSmithKline: Gastroenteritis trials

The registry lists 25 Gastroenteritis studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 2 3Phase 3 6Phase 4 1No phase 15(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese InfantsCompletedNCT06331156Phase 3Results posted
• Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 WeeksCompletedNCT06025695Phase 3Results posted
• Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean InfantsCompletedNCT00969228Phase 4Results posted
• Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Indian InfantsCompletedNCT00938327Results posted
• Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in InfantsCompletedNCT00779779Results posted
• Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in InfantsCompletedNCT00750893Results posted
• A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.CompletedNCT00432380Phase 2Results posted
• Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.CompletedNCT00420316Phase 3Results posted
• A Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.CompletedNCT00396630Phase 3Results posted
• To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First VaccinationCompletedNCT00353366Results posted
• Impact of Rotavirus Vaccination on Hospital Pressures at a Large Paediatric Hospital in the UK: an Ecological StudyCompletedNCT03271593
• Surveillance Study to Estimate the Proportion of Rotavirus Gastroenteritis in Children < 5 Years of Age in RomaniaCompletedNCT01253967
• Impact of Rotavirus Vaccination on Hospitalisations for Rotavirus Gastroenteritis in Children Aged <5 Years in AustraliaCompletedNCT01236066
• A Retrospective Survey of the Burden of Rotavirus Gastroenteritis (RV GE) and Nosocomial RV GE in JapanCompletedNCT01202201
• Study to Estimate the Disease Burden of Acute Rotavirus Gastroenteritis in Children < 5 Years in United Arab EmiratesCompletedNCT01201252
• Effectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized ChildrenCompletedNCT01177826
• Study to Evaluate the Effectiveness of Rotarix™ Against Severe Gastroenteritis Among Hospitalized Children in BrazilCompletedNCT01177657
• Trends Over Time (1990-2010) of Diarrhoea-related Hospitalizations and Deaths in Children < 5 Years of Age in BrazilCompletedNCT01175252
• Trends Over Time (1990-2010) of Diarrhoea-related Incidence, Hospitalizations and Deaths in Children of PanamaCompletedNCT01171144
• Assessment of Clinical Consistency of Three Production Lots of GSK Biologicals' HRV VaccineCompletedNCT00757770Phase 3
• Estimation of the Burden of Rotavirus Gastroenteritis (RV GE) in Children Less Than 5 Years in GreeceCompletedNCT00751686
• Effectiveness of Human Rotavirus Vaccine, Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) in InfantsCompletedNCT00655187
• Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine at Different Viral Concentrations in Healthy InfantsCompletedNCT00429481Phase 2
• Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy InfantsCompletedNCT00425737Phase 2
• Assess the Immunogenicity of the Human Rotavirus (HRV) Vaccine After Reconstitution Without Buffering Agent; & Evaluate the Immunogenicity, Reactogenicity & Safety of the Vaccine After Storage for 7 d at 37°C Following 2 Doses in Healthy InfantsCompletedNCT00169455Phase 3